Balchem 過去の業績
過去 基準チェック /56
Balchemは、平均年間11.2%の収益成長を遂げていますが、 Chemicals業界の収益は、年間 減少しています。収益は、平均年間4% 6%収益成長率で 成長しています。 Balchemの自己資本利益率は12.3%であり、純利益率は15%です。
主要情報
11.20%
収益成長率
11.08%
EPS成長率
| Chemicals 業界の成長 | 12.93% |
| 収益成長率 | 5.96% |
| 株主資本利益率 | 12.30% |
| ネット・マージン | 14.95% |
| 前回の決算情報 | 31 Mar 2026 |
最近の業績更新
Recent updates
Seeking Alpha • Mar 27
Balchem: An Attractive Valuation Makes This Stock A Buy
Summary Balchem delivered strong Q4 results, with revenue up nearly 10% year-over-year and all segments posting growth. BCPC boasts a 17-year streak of double-digit dividend hikes, supported by a payout ratio consistently below 20%. The stock trades at a roughly 25% discount to its estimated fair value, with robust forward return potential exceeding 14%. I rate BCPC a 'Buy', citing resilient segment demand, disciplined capital allocation, and attractive free cash flow valuation despite raw material and tariff risks. Read the full article on Seeking Alpha
新しいナラティブ • Mar 13
Long-Term Nutrition And Health Trends Will Support Stronger Margins And Earnings Potential
Catalysts About Balchem Balchem supplies specialty nutrients and ingredients for human, animal and plant health, along with performance gases and related solutions. What are the underlying business or industry changes driving this perspective?
新しいナラティブ • Feb 26
Encapsulation Investments And International Expansion Will Shape Balanced Future For Nutrition Specialist
Catalysts About Balchem Balchem produces specialty nutrition and ingredient solutions for human, animal and plant health, along with performance gases. What are the underlying business or industry changes driving this perspective?
ナラティブの更新 • Feb 17
BCPC: Dividend Increase And Buyback Program Will Support Steady Future Returns
Analysts kept their Balchem fair value estimate broadly steady at $191, pointing to only very small tweaks in assumptions such as discount rate, long term revenue growth, profit margin and future P/E as the basis for maintaining their target level. What's in the News On December 9, 2025, Balchem Corporation's Board of Directors declared an annual dividend of $0.96 per share, payable on January 20, 2026, to stockholders of record as of December 23, 2025.分析記事 • Feb 15
If EPS Growth Is Important To You, Balchem (NASDAQ:BCPC) Presents An Opportunity
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...ナラティブの更新 • Feb 03
BCPC: Share Repurchases And Higher Dividend Will Support Attractive Future Returns
Analysts have maintained their fair value estimate for Balchem at US$191. They have made only minimal adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions, indicating that their overall view on the stock's valuation drivers remains essentially unchanged.分析記事 • Feb 01
Is Now An Opportune Moment To Examine Balchem Corporation (NASDAQ:BCPC)?
Balchem Corporation ( NASDAQ:BCPC ), is not the largest company out there, but it saw a decent share price growth of...ナラティブの更新 • Jan 20
BCPC: Share Repurchases And Rising Dividend Will Support Attractive Future Returns
Analysts have maintained their Balchem fair value estimate at US$191, with only small tweaks to the discount rate, revenue growth, profit margin, and forward P/E assumptions. This reflects a largely unchanged view on the stock's risk and earnings profile.ナラティブの更新 • Jan 05
BCPC: Share Repurchases And Dividend Increases Will Support Attractive Future Returns
Analysts kept their fair value estimate for Balchem steady at US$191, pointing to only very small model tweaks in the discount rate, revenue growth, margin and forward P/E assumptions rather than any change in their overall view of the company. What's in the News Balchem Corporation announced a share repurchase program authorizing the company to buy back up to 4,000,000 shares, with no expiration date on the program (Key Developments).ナラティブの更新 • Dec 20
BCPC: Share Repurchases And Dividend Increases Will Drive Attractive Future Returns
Analysts have maintained their price target on Balchem at approximately $191.00. This reflects only marginal tweaks to underlying assumptions such as discount rate, revenue growth, and profit margin, rather than a material change in their outlook.ナラティブの更新 • Dec 06
BCPC: Share Repurchases Will Support Attractive Long Term Return Potential
Analysts have lowered their price target on Balchem by approximately $9 to about $191 per share, reflecting more cautious assumptions around revenue growth and profit margins, even though long term valuation multiples are slightly higher. What's in the News Completed a long running share repurchase program, buying back a total of 3,475,622 shares, or about 12.76% of shares outstanding, for approximately $190.58 million since the authorization began in 1999 (Key Developments) During the most recent quarter from July 1, 2025 to September 30, 2025, repurchased 95,760 shares, roughly 0.3% of shares outstanding, for $15.42 million as the final tranche under the existing buyback plan (Key Developments) Valuation Changes The Fair Value Estimate has fallen modestly from about $200.33 to $191.00 per share, reflecting a slightly more conservative outlook.分析記事 • Dec 01
Balchem (NASDAQ:BCPC) Is Experiencing Growth In Returns On Capital
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...分析記事 • Oct 10
Some Shareholders Feeling Restless Over Balchem Corporation's (NASDAQ:BCPC) P/E Ratio
Balchem Corporation's ( NASDAQ:BCPC ) price-to-earnings (or "P/E") ratio of 31.9x might make it look like a strong sell...分析記事 • Sep 26
Balchem (NASDAQ:BCPC) Could Easily Take On More Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Aug 26
Estimating The Fair Value Of Balchem Corporation (NASDAQ:BCPC)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Balchem fair value estimate is US$174 With US$162 share price...分析記事 • Jul 21
Balchem (NASDAQ:BCPC) Is Looking To Continue Growing Its Returns On Capital
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...分析記事 • Jun 23
These 4 Measures Indicate That Balchem (NASDAQ:BCPC) Is Using Debt Safely
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Oct 28
Balchem's Q3 Shows Record Earnings And Valuation Pressure
Summary Balchem Corporation shows strong long-term growth potential in high-margin segments and product innovation, but faces challenges in Animal Nutrition & Health and rising costs. Balchem's financial momentum in Q3 2024 includes record earnings, improved margins, and significant debt reduction, despite missing revenue estimates. BCPC stock's high P/E ratio of 39.82x suggests big market expectations, but the current valuation may be too high given existing challenges. I rate Balchem as a “Hold” due to high valuation, operational challenges, and potential seasonal slowdown, advising cautious investors to wait for a better entry point. Read the full article on Seeking Alpha
新しいナラティブ • Aug 29
Innovating In Nutrition And Health Sectors Drives Strong Financial Growth And Market Expansion
Launch of Optifolin+ in the nutrition segment and strong Human Nutrition & Health sales indicate potential for market share expansion and sustained revenue growth.Seeking Alpha • May 10
Balchem: A Tale Of Two Businesses
Summary Balchem Corporation's Q1 2024 earnings surpassed expectations, but the company's full-year bottom-line expansion could be slower than what it achieved for the first quarter. The Human Nutrition & Health segment is riding on the supplements market's growth, while the Animal Nutrition & Health segment is encountering stiff competition in the European animal feed market. It is a tale of two businesses for BCPC, which implies that the stock warrants a Neutral or Hold rating. Read the full article on Seeking AlphaSeeking Alpha • Feb 21
Balchem: Potential Turnaround Is In The Price
Summary Balchem registered a -2.5% top-line miss for the fourth quarter of 2023, which is attributable to the underperformance of its Animal Nutrition business. BCPC is well-positioned to achieve positive top line and earnings expansion in the current year, but I deem the stock's valuations to be fair. The Company continues to be rated as a Hold, as my opinion is that the expected 2024 turnaround for BCPC is priced in. Read the full article on Seeking Alpha収支内訳
収支内訳
Balchem の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 31 Mar 26 | 1,057 | 158 | 149 | 20 |
| 31 Dec 25 | 1,037 | 155 | 143 | 19 |
| 30 Sep 25 | 1,014 | 149 | 140 | 18 |
| 30 Jun 25 | 986 | 143 | 136 | 18 |
| 31 Mar 25 | 965 | 137 | 133 | 17 |
| 31 Dec 24 | 954 | 128 | 136 | 17 |
| 30 Sep 24 | 942 | 122 | 144 | 16 |
| 30 Jun 24 | 932 | 117 | 139 | 16 |
| 31 Mar 24 | 930 | 115 | 131 | 16 |
| 31 Dec 23 | 922 | 109 | 120 | 15 |
| 30 Sep 23 | 926 | 103 | 117 | 14 |
| 30 Jun 23 | 941 | 99 | 122 | 13 |
| 31 Mar 23 | 946 | 99 | 126 | 12 |
| 31 Dec 22 | 942 | 105 | 121 | 12 |
| 30 Sep 22 | 923 | 109 | 116 | 14 |
| 30 Jun 22 | 877 | 109 | 109 | 14 |
| 31 Mar 22 | 842 | 102 | 107 | 14 |
| 31 Dec 21 | 799 | 96 | 102 | 14 |
| 30 Sep 21 | 767 | 93 | 100 | 11 |
| 30 Jun 21 | 744 | 90 | 100 | 11 |
| 31 Mar 21 | 715 | 88 | 99 | 10 |
| 31 Dec 20 | 704 | 85 | 102 | 10 |
| 30 Sep 20 | 689 | 83 | 104 | 11 |
| 30 Jun 20 | 673 | 82 | 104 | 11 |
| 31 Mar 20 | 661 | 81 | 102 | 11 |
| 31 Dec 19 | 644 | 80 | 95 | 11 |
| 30 Sep 19 | 641 | 80 | 89 | 12 |
| 30 Jun 19 | 637 | 78 | 84 | 12 |
| 31 Mar 19 | 639 | 78 | 82 | 12 |
| 31 Dec 18 | 644 | 79 | 84 | 12 |
| 30 Sep 18 | 639 | 100 | 83 | 11 |
| 30 Jun 18 | 635 | 97 | 84 | 11 |
| 31 Mar 18 | 618 | 94 | 81 | 10 |
| 31 Dec 17 | 595 | 90 | 81 | 9 |
| 30 Sep 17 | 576 | 64 | 82 | 9 |
| 30 Jun 17 | 564 | 62 | 82 | 8 |
| 31 Mar 17 | 556 | 60 | 82 | 7 |
| 31 Dec 16 | 553 | 56 | 83 | 7 |
| 30 Sep 16 | 545 | 56 | 77 | 7 |
| 30 Jun 16 | 547 | 56 | 76 | 7 |
| 31 Mar 16 | 543 | 56 | 72 | 6 |
| 31 Dec 15 | 552 | 60 | 68 | 6 |
| 30 Sep 15 | 582 | 63 | 71 | 6 |
| 30 Jun 15 | 603 | 64 | 70 | 6 |
質の高い収益: BCPCは 高品質の収益 を持っています。
利益率の向上: BCPCの現在の純利益率 (15%)は、昨年(14.2%)よりも高くなっています。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: BCPCの収益は過去 5 年間で年間11.2%増加しました。
成長の加速: BCPCの過去 1 年間の収益成長率 ( 15.8% ) は、5 年間の平均 ( 年間11.2%を上回っています。
収益対業界: BCPCの過去 1 年間の収益成長率 ( 15.8% ) はChemicals業界0.1%を上回りました。
株主資本利益率
高いROE: BCPCの 自己資本利益率 ( 12.3% ) は 低い とみなされます。
総資産利益率
使用総資本利益率
過去の好業績企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/27 08:43 |
| 終値 | 2026/05/27 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Balchem Corporation 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9
| アナリスト | 機関 |
|---|---|
| Robert Labick | CJS Securities, Inc. |
| Timothy Ramey | D.A. Davidson & Co. |
| Raghuram Selvaraju | H.C. Wainwright & Co. |